Home » Allergy Therapeutics Plc
Allergy Therapeutics plc

Allergy Therapeutics Plc



Website:
https://www.allergytherapeutics.com

UK Address:
Dominion Way,
Worthing,
West Sussex,
BN14 8SA,
United Kingdom


Tel +44 (0)1903 844 700

Industry:


Market Cap:

  ( )

Market Cap:
Opening Price:
Day High:
Day Low:
Previous Close:

52 Week High:
52 Week Low:

Highlights

  • Market leading, pioneering immunology business
  • Specialist experience in R&D of allergy treatments
  • Focus on direct treatment of the cause
  • Vaccines are aluminium free
  • Ultra-short course treatments
  • Adjuvant technologies advance results of allergy immunotherapy
  • Adjuvant technologies drive beneficial immune responses in cancer
  • Passionate team of scientists and business specialists with a vision

Board of Directors

  • Peter Jensen - Non-Executive Chairman
  • Stephen Smith - Non-Executive Director
  • Tunde Otulana - Non-Executive Director
  • Manuel Llobet - Chief Executive Officer
  • Nick Wykeman - Chief Finance Officer
  • Scott Leinenweber - Non-Executive Director

News & Interviews

Allergy Therapeutics Plc (LON:AGY) is the topic of conversation with Dr Gary Waanders Director of Healthcare Research at Zeus Capital. Since Allergy Therapeutics announced today that it has obtained approval to begin a phase I clinical trial of its Acarovac MPL vaccine in Spain, Gary explains what the product designed to do, what CTA clearance means for the product’s development and on the basis of a fully approved vaccine the sort of sales he thinks might be possible.

Gary is an experienced healthcare analyst having worked in the City since early 2001. He joined Zeus in January 2014 and is responsible for research coverage of all our Life Sciences corporate clients which include companies active in biotechnology, specialty pharmaceuticals, medical technology and clinical research services. He has worked on numerous IPOs and M&A mandates in the UK and Europe and has previously worked at Nomura Code Securities and KBC Peel Hunt. Prior to becoming an analyst, he managed an R&D group at a Canadian biotech company and before that he was a post-doctoral fellow at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland. His academic training includes an MBA from the University of Durham Business School and a PhD in Immunology from the Faculty of Medicine at Monash University (Australia) where he also obtained a BSc (Hons) in Immunology and Biochemistry.

Allergy Therapeutics plc is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.495 employees and is listed on the London Stock Exchange.

1 2 3 7

Join us on our new LinkedIn page

Follow us on LinkedIn